Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Negative elongation factor complex member A (NELFA) is an essential subunit of the NELF complex, which consists of four proteins (NELF-A, NELF-B, NELF-C/NELF-D, and NELF-E). NELFA regulates transcription elongation by RNA polymerase II, enforcing promoter-proximal pausing and coordinating mRNA processing, especially at histone gene loci[1][5][13]. It is ubiquitously expressed, with higher levels in fetal tissues, and is mapped to chromosome 4p16.3, the critical region for Wolf-Hirschhorn syndrome[4][8][14]. NELFA's modulation—via phosphorylation, SUMOylation, or interaction with DSIF—controls transcriptional output in response to developmental and environmental cues. It is implicated in disease contexts including cancer, due to its immunogenic properties, and congenital disorders associated with 4p deletions (WHS), and may have relevance for HIV-1 latency[2][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Negative elongation factor complex member A (NELFA).